Our business development plan is aligned with our recently established Next-Generation Biomanufacturing facility in Singapore, which will manufacture some of the products that we’ll be commercializing…
In Conversation
Local competency and efficiency is really important to achieve such growth rates—making sure that the organization is able to get more by expending less
For most of the German companies in Singapore, the city state is the hub for the region because of its location, the good infrastructure, the connectivity,…
At the crux of bioMérieux Industry’s vision is to provide solutions for the prevention of microbiological contamination and ensure overall consumer safety
"In Singapore, it is about creating the right environment so that companies can benefit from the capabilities that we have built. Companies then adopt and pivot…
The Duke-NUS partnership has been focused on developing medical practitioners interested in research and innovation
No matter which market you are in, you are starting to see an evolution of how stakeholders choose to engage with pharmaceutical companies
Singapore is the best place in Asia to grow a healthcare business as a result of high government involvement, a business friendly ecosystem with regional access,…
As an academic institute we support investigator-led studies that private pharmaceutical companies may not be interested because of the low potential profits. However, the substantial impact…
Since its establishment, BioSingapore has increased its membership and now has more than 100 associated individuals and around 30 member companies.
We spend 5.1% of our GDP on health care, while the OECD countries spend an average of 9.3%.
We see ourselves as filling the space between academic research in the universities and the corporate research that takes place in industry
